secretoglobin family 3A member 1Genealiases: HIN-1 · HIN1 · LU105 · PnSP-2 · UGRP2
Q-omics provides the consensus-scored SCGB3A1 profile across patient tissues and cancer cell-line models. SCGB3A1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SCGB3A1 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, SCGB3A1 RNA expression shows 16,743 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUAD, and LSCC as cancer lineages where SCGB3A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCGB3A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCGB3A1 survival associations across molecular data types. SCGB3A1 RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCGB3A1 RNA expression–survival associations across cancer types. High SCGB3A1 expression shows unfavorable associations in BLCA, but favorable associations in KIRC, ACC, LGG, THYM and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SCGB3A1 RNA expression.
This table summarizes SCGB3A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SCGB3A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCGB3A1 shows lower tumor expression in LUAD, LUSC, KICH, LIHC and HNSC and higher tumor expression in KIRC. The LUAD box plot shows higher SCGB3A1 RNA expression in normal versus tumor tissue (log2 FC = −4.184, t-test p < 0.001).
This table shows molecular features associated with SCGB3A1 in patient tissues and cancer cell lines. In patient samples, SCGB3A1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SCGB3A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and CNS.
